0 680

Cited 48 times in

1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: 1-Month DAPT Trial

DC Field Value Language
dc.contributor.author고영국-
dc.contributor.author김병극-
dc.contributor.author김중선-
dc.contributor.author남정모-
dc.contributor.author안철민-
dc.contributor.author장양수-
dc.contributor.author최동훈-
dc.contributor.author홍명기-
dc.contributor.author홍성진-
dc.date.accessioned2021-09-29T02:08:24Z-
dc.date.available2021-09-29T02:08:24Z-
dc.date.issued2021-07-
dc.identifier.issn1936-8798-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184733-
dc.description.abstractObjectives: The aim of this study was to determine whether 1 month of dual-antiplatelet therapy (DAPT) followed by aspirin monotherapy after polymer-free drug-coated stent (PF-DCS) implantation is noninferior to 6 to 12 months of DAPT after biodegradable-polymer drug-eluting stent (BP-DES) implantation. Background: It is necessary to determine the optimal minimal duration of DAPT followed by aspirin monotherapy after percutaneous coronary intervention (PCI). Methods: In this trial, 3,020 patients with coronary artery disease considered for PCI for noncomplex lesions were randomized to 1-month DAPT after PF-DCS (n = 1,507) or 6- to 12-month DAPT after BP-DES (n = 1,513). The primary endpoint was the 1-year composite of cardiac death, nonfatal myocardial infarction, target vessel revascularization, stroke, or major bleeding (noninferiority hypothesis margin of 3%). Results: The primary endpoint occurred in 88 patients (5.9%) in the 1-month DAPT after PF-DCS group and 98 patients (6.5%) in the 6- to 12-month DAPT after BP-DES group (absolute difference -0.7%; upper limit of 1-sided 97.5% confidence interval: 1.33%; P < 0.001 for noninferiority). The occurrence of major bleeding was not different (1.7% vs 2.5%; P = 0.136). There was no difference in the occurrence of stent thrombosis (0.7% vs 0.8%; P = 0.842). Conclusions: Among patients who underwent PCI for noncomplex lesions, 1-month DAPT followed by aspirin monotherapy after PF-DCS implantation was noninferior to 6- to 12-month DAPT after BP-DES implantation for the 1-year composite of cardiovascular events or major bleeding. The present findings need to be interpreted in the setting of different types of stents according to antiplatelet strategy. (A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-Eluting Stent Implantation; NCT02513810).-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfJACC-CARDIOVASCULAR INTERVENTIONS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: 1-Month DAPT Trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorSung-Jin Hong-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorSoon Jun Hong-
dc.contributor.googleauthorDo-Sun Lim-
dc.contributor.googleauthorSeung-Yul Lee-
dc.contributor.googleauthorKyeong Ho Yun-
dc.contributor.googleauthorJong-Kwan Park-
dc.contributor.googleauthorWoong Chol Kang-
dc.contributor.googleauthorYong Hoon Kim-
dc.contributor.googleauthorHyuck-Jun Yoon-
dc.contributor.googleauthorHoyoun Won-
dc.contributor.googleauthorChung-Mo Nam-
dc.contributor.googleauthorChul-Min Ahn-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorYangsoo Jang-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.identifier.doi10.1016/j.jcin.2021.06.003-
dc.contributor.localIdA00127-
dc.contributor.localIdA00493-
dc.contributor.localIdA00961-
dc.contributor.localIdA01264-
dc.contributor.localIdA02269-
dc.contributor.localIdA03448-
dc.contributor.localIdA04053-
dc.contributor.localIdA04391-
dc.contributor.localIdA04403-
dc.relation.journalcodeJ01193-
dc.identifier.eissn1876-7605-
dc.identifier.pmid34332946-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S193687982101045-
dc.subject.keywordantiplatelet therapy-
dc.subject.keyworddrug-eluting stents-
dc.subject.keywordpercutaneous coronary intervention-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.affiliatedAuthor고영국-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor남정모-
dc.contributor.affiliatedAuthor안철민-
dc.contributor.affiliatedAuthor장양수-
dc.contributor.affiliatedAuthor최동훈-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor홍성진-
dc.citation.volume14-
dc.citation.number16-
dc.citation.startPage1801-
dc.citation.endPage1811-
dc.identifier.bibliographicCitationJACC-CARDIOVASCULAR INTERVENTIONS, Vol.14(16) : 1801-1811, 2021-07-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.